US 10,376,509 B2
Pharmaceutical compositions comprising clofazimine analog compound B746 or clofazimine analog compound B826
Venkata M. Reddy, Gaithersburg, MD (US); Wolf Prensky, Germantown, MD (US); and Sharanjit VedBrat, Germantown, MD (US)
Assigned to KamTek, Inc., Frederick, MD (US)
Filed by KamTeK, Inc., Frederick, MD (US)
Filed on Aug. 22, 2018, as Appl. No. 16/108,879.
Application 16/108,879 is a division of application No. 15/831,237, filed on Dec. 4, 2017, granted, now 10,064,860.
Application 15/831,237 is a division of application No. 15/421,982, filed on Feb. 1, 2017, granted, now 9,849,130, issued on Dec. 26, 2017.
Application 15/421,982 is a division of application No. 14/947,212, filed on Nov. 20, 2015, abandoned.
Claims priority of provisional application 62/082,925, filed on Nov. 21, 2014.
Claims priority of provisional application 62/133,058, filed on Mar. 13, 2015.
Prior Publication US 2018/0360826 A1, Dec. 20, 2018
Int. Cl. A61K 31/498 (2006.01); A61K 38/14 (2006.01); A61K 31/4164 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/498 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4164 (2013.01); A61K 31/7048 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01)] 9 Claims
 
1. A method for inhibiting the activity of Clostridium difficile in a subject, comprising administering to the subject in need thereof a pharmaceutical composition consisting of at least one pharmaceutically acceptable excipient and a compound selected from the group consisting of:

OG Complex Work Unit Drawing